Adrestia Therapeutics

Adrestia is a leader in synthetic rescue therapies for genetic diseases. As many directly causative mutations are not druggable, synthetic rescue embraces the much broader target set within related pathways to correct the effects of the causative mutations and 'rescue' health. Adrestia is creating a synthetic rescue 'atlas' of the human genome and... advancing a portfolio of first-in-class therapies, initially for neurological, neuromuscular and cardiomyopathic diseases. Adrestia's platform and in-house programs are complemented by a target discovery alliance with GSK and a Huntington's disease collaboration with noted researchers including Dr. Sarah Tabrizi at University College London. Adrestia was co-founded by Professor Steve Jackson and the deep technology investment fund Ahren Innovation Capital, which co-led Adrestia's Series A financing along with GSK. Jackson co-originated the first synthetic lethality drug, olaparib, which was the first drug approved to treat cancers caused by inherited mutations.Read More